Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Emma J. Eshuis"'
Autor:
Jan van den Brande, Tessa Uiterwaal, Christianne J. Buskens, Juda Vecht, Robert E G J M Pierik, Job H.C. Peters, Nofel Mahmmod, John Maring, E. Joline de Groof, Toer W. Stevens, H. B. A. C. Stockmann, Pieter C. F. Stokkers, Karlien F. Bruin, Eric J. Hazebroek, Ailsa Hart, Arnold van de Laar, Hubert A Prins, Richard van Hillegersberg, Rachel L. West, Paul Kingma, Menno A. Brink, Pritesh Morar, Ruud Schouten, Marno C.M. Rijk, A Jeroen de Groof, Sijbrand Hofker, Annekatrien Depla, Bregje Mol, Janneke van der Woude, T. J. Gardenbroek, Janindra Warusavitarne, Bas Oldenburg, Edwin S. van der Zaag, Anna A. W. van Geloven, Rogier M P H Crolla, Emma J. Eshuis, Hans Brouwer, Meindert N. Sosef, Maria L Haasnoot, Geert R. D'Haens, Nynke Talstra, Marcel Spanier, Liekele Oostenbrug, Jeroen M. Jansen, Maarten J Boom, Donald L. van der Peet, Nanne K. H. de Boer, Willem A. Bemelman, Cyriel Y. Ponsioen, Rosalie C Mallant, Theo J.M. van Ditzhuijsen, Gerard Dijkstra, Alexander P.J. Houdijk, Willem A. Marsman, Djuna Cahen, Casper G. Noomen, Huib A. Cense, Esther C. J. Consten, Michael F. Gerhards, Ad A. van Bodegraven, Rob J. Lieverse, Andreas Marinelli, Sjoerd van der Werff, Clemens Bolwerk, Ernst Jan Spillenaar Bilgen, Quirijn A. J. Eijsbouts, Guido Mannaerts, Bart A. van Wagensveld
Publikováno v:
The lancet. Gastroenterology & hepatology, 5(10), 900-907. HANLEY & BELFUS-ELSEVIER INC
LIR!C study group 2020, ' Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease : retrospective long-term follow-up of the LIR!C trial ', The Lancet Gastroenterology and Hepatology, vol. 5, no. 10, pp. 900-907 . https://doi.org/10.1016/S2468-1253(20)30117-5
The Lancet Gastroenterology and Hepatology, 5(10), 900-907. Elsevier Ltd
lancet. Gastroenterology & hepatology, 5(10), 900-907. Elsevier Limited
LIR!C study group 2020, ' Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease : retrospective long-term follow-up of the LIR!C trial ', The Lancet Gastroenterology and Hepatology, vol. 5, no. 10, pp. 900-907 . https://doi.org/10.1016/S2468-1253(20)30117-5
The Lancet Gastroenterology and Hepatology, 5(10), 900-907. Elsevier Ltd
lancet. Gastroenterology & hepatology, 5(10), 900-907. Elsevier Limited
BACKGROUND: The LIR!C trial showed that laparoscopic ileocaecal resection is a cost-effective treatment that has similar quality-of-life outcomes to treatment with infliximab, an anti-tumour necrosis factor (TNF) drug. We aimed to compare long-term o
Autor:
Severine Vermeire, Albert Wolthuis, W. A. Bemelman, G. D'Haens, Ann Belmans, Christianne J. Buskens, G. Van Assche, Emma J. Eshuis, Marc Ferrante, A. de Buck van Overstraeten, André D'Hoore, C.Y. Ponsioen
Publikováno v:
British journal of surgery, 104(12), 1713-1722. John Wiley and Sons Ltd
Background Despite improvements in medical therapy, the majority of patients with Crohn's disease still require surgery. The aim of this study was to report safety, and clinical and surgical recurrence rates, including predictors of recurrence, after
Autor:
Job H.C. Peters, Sijbrand Hofker, Marno C.M. Rijk, Theo J.M. van Ditzhuijsen, Donald L. van der Peet, Annekatrien Depla, John Maring, Hans Brouwer, Geert R. D'Haens, Anna A. W. van Geloven, Patrick M.M. Bossuyt, Huib A. Cense, Paul Kingma, Djuna Cahen, Meindert N. Sosef, Esther C. J. Consten, Arnold van de Laar, H. B. A. C. Stockmann, Emma J. Eshuis, Richard van Hillegersberg, Ernst Jan Spillenaar Bilgen, Karlien F. Bruin, Bregje Mol, Alexander P.J. Houdijk, Liekele Oostenbrug, Jeroen M. Jansen, Maarten J Boom, Robert E G J M Pierik, Gerard Dijkstra, Hubert A Prins, Rogier M P H Crolla, Rosalie C Mallant, Nanne K. H. de Boer, Jan van den Brande, Michael F. Gerhards, Ad A. van Bodegraven, Menno A. Brink, Bas Oldenburg, Pritesh Morar, Janneke van der Woude, Janindra Warusavitarne, Tjibbe J. Gardenbroek, E. Joline de Groof, Pieter C. F. Stokkers, Rob J. Lieverse, Eric J. Hazebroek, Marcel Spanier, Casper G. Noomen, Willem A. Bemelman, Cyriel Y. Ponsioen, Andreas Marinelli, Juda Vecht, Ailsa Hart, Nynke Talstra, Willem A. Marsman, Tessa Uiterwaal, Christianne J. Buskens, Nofel Mahmmod, Rachel L. West, A Jeroen de Groof, Sjoerd van der Werff, Clemens Bolwerk, Quirijn A. J. Eijsbouts, Edwin S. van der Zaag, Ruud Schouten, Bart A. van Wagensveld, Guido Mannaerts
Publikováno v:
Ponsioen, C Y, de Groof, E J, Eshuis, E J, Gardenbroek, T J, Bossuyt, P M M, Hart, A, Warusavitarne, J, Buskens, C J, van Bodegraven, A A, Brink, M A, Consten, E C J, van Wagensveld, B A, Rijk, M C M, Crolla, R M P H, Noomen, C G, Houdijk, A P J, Mallant, R C, Boom, M, Marsman, W A, Stockmann, H B, Mol, B, de Groof, A J, Stokkers, P C, D'Haens, G R, Bemelman, W A, LIR!C study group & LIR!C study group 2017, ' Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease : a randomised controlled, open-label, multicentre trial ', The Lancet Gastroenterology and Hepatology, vol. 2, no. 11, pp. 785-792 . https://doi.org/10.1016/S2468-1253(17)30248-0
Lancet Gastroenterology & Hepatology, 2(11), 785-792. Elsevier Ltd.
The Lancet Gastroenterology and Hepatology, 2(11), 785-792. Elsevier Ltd
lancet. Gastroenterology & hepatology, 2(11), 785-792. Elsevier Limited
Lancet Gastroenterology & Hepatology, 2(11), 785-792. Elsevier Ltd.
The Lancet Gastroenterology and Hepatology, 2(11), 785-792. Elsevier Ltd
lancet. Gastroenterology & hepatology, 2(11), 785-792. Elsevier Limited
Background Treatment of patients with ileocaecal Crohn's disease who have not responded to conventional therapy is commonly scaled up to biological agents, but surgery can also offer excellent short-term and long-term results. We compared laparoscopi
Autor:
Bregje Mol, G. D'Haens, Emma J. Eshuis, Pieter C. F. Stokkers, T Gardenbroef, Cyriel I J Ponsioen, Christianne J. Buskens, W. A. Bemelman, L Haasnoot, Toer W. Stevens, Lir!C, E. J. de Groof
Publikováno v:
Journal of Crohn's and Colitis. 14:S003-S004
Background The LIR!C trial showed that laparoscopic ileocaecal resection is at least as good as anti-TNF in terms of quality of life and is cost-saving. Current aims were to compare the long-term outcome of both interventions and to identify factors
Autor:
Laura Haasnoot, Christianne J. Buskens, Willem A. Bemelman, Cyriel Y. Ponsioen, Geert R. D'Haens, Emma J. Eshuis, Toer W. Stevens, Tjibbe J. Gardenbroek, E. Joline de Groof, Pieter C. F. Stokkers, Bregje Mol
Publikováno v:
Gastroenterology. 158:S-55
Autor:
Adriaan A. van Bodegraven, Emma J. Eshuis, Jeroen M. Jansen, Charlotte P. Peters, Geert R. D'Haens, Florien M. Toxopeüs, Paul Fockens, Merel E. Hellemons, Pieter C. F. Stokkers, Hans Tuynman, Cyriel Y. Ponsioen
Publikováno v:
Journal of Crohn's and Colitis, 8(8), 866-875. Elsevier
Journal of Crohn s & colitis, 8(8), 866-875. Elsevier
Peters, C P, Eshuis, E J, Toxopeus, F M, Hellemons, M E, Jansen, J M, D'Haens, G R A M, Fockens, P, Stokkers, P C F, Tuynman, H A R E, van Bodegraven, A A & Ponsioen, C Y 2014, ' Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients ', Journal of Crohn's and Colitis, vol. 8, no. 8, pp. 866-875 . https://doi.org/10.1016/j.crohns.2014.01.012
Journal of Crohn s & colitis, 8(8), 866-875. Elsevier
Peters, C P, Eshuis, E J, Toxopeus, F M, Hellemons, M E, Jansen, J M, D'Haens, G R A M, Fockens, P, Stokkers, P C F, Tuynman, H A R E, van Bodegraven, A A & Ponsioen, C Y 2014, ' Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients ', Journal of Crohn's and Colitis, vol. 8, no. 8, pp. 866-875 . https://doi.org/10.1016/j.crohns.2014.01.012
Adalimumab is an effective therapy for induction and maintenance of Crohn's disease. However, results in clinical trials don't necessarily reflect daily clinical practice. Therefore, we assessed real-life long-term clinical response to adalimumab in
Autor:
Willem A. Bemelman, Cyriel Y. Ponsioen, Emma J. Eshuis, Pieter J. Tanis, Rana L. Al Saady, Pieter C. F. Stokkers
Publikováno v:
Journal of Crohn s & colitis, 7(2), 142-149. Elsevier
Background and aims It is unclear whether infliximab treatment induces increased complication rates after surgery for ulcerative colitis. Aim was to compare complication rates after pouch surgery in refractory ulcerative colitis patients with versus
Publikováno v:
Colorectal Disease. 14:578-584
Aim Although the occurrence of intestinal perforation in Crohns disease (CD) is rare, clinical observation has led to the question whether anti tumour necrosis factor (TNF) treatment is a risk factor for free perforation. The aim of this study was to
Autor:
Geert R. D'Haens, Emma J. Eshuis, W. A. Bemelman, Tjibbe J. Gardenbroek, C. I. J. Ponsioen, Dirk T. Ubbink
Publikováno v:
Colorectal Disease. 14:545-553
Aim Previous studies have shown significantly lower appendectomy rates in ulcerative colitis (UC) patients compared with healthy controls. Evidence indicating that the appendix has an immunomodulatory role in UC has been accumulating. To examine the
Autor:
Esther C. J. Consten, Judith E. Bosmans, Emma J. Eshuis, Cyriel I J Ponsioen, Christianne J. Buskens, Pieter C. F. Stokkers, G. D'Haens, Menno A. Brink, Peter Bossuyt, B. van Wagensveld, W. A. Bemelman, T. J. Gardenbroek, J. de Groof, H. van Dongen
Publikováno v:
Journal of Crohn's and Colitis. 11:S9-S10